Canada - English - Health Canada

novo nordisk canada inc - semaglutide - solution - 0.68mg - semaglutide 0.68mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - semaglutide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - semaglutide -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - semaglutide - solution for injection - 1.34mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - semaglutide - solution for injection - 1.34mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - semaglutide - solution for injection - 1.34mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 7 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 3.2 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - adults,wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial body mass index (bmi) of,? ?30 kg/m2 (obesity), or,? ?27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see section 5.1 pharmacodynamic properties ? clinical trials).,adolescents,wegovy? is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,? obesity* or,? body weight above 60 kg,treatment with wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their bmi by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*obesity (bmi ? 95th percentile) as defined on sex- and age-specific bmi growth charts (cdc.gov) (see table 1).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 3 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 2.27 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - adults,wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial body mass index (bmi) of,? ?30 kg/m2 (obesity), or,? ?27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see section 5.1 pharmacodynamic properties ? clinical trials).,adolescents,wegovy? is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,? obesity* or,? body weight above 60 kg,treatment with wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their bmi by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*obesity (bmi ? 95th percentile) as defined on sex- and age-specific bmi growth charts (cdc.gov) (see table 1).